Italia markets close in 48 minutes

BioNTech SE (BNTX)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
164,77-3,10 (-1,84%)
Al 10:40AM EDT. Mercato aperto.
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente167,87
Denaro164,39 x 1000
Lettera164,68 x 800
Min-Max giorno164,18 - 169,26
Intervallo di 52 settimane121,32 - 464,00
Media Volume1.610.225
Beta (5 anni mensile)-0,28
Rapporto PE (ttm)3,16
EPS (ttm)52,10
Prossima data utili08 ago 2022
Rendimento e dividendo (forward)2,11 (1,32%)
Data ex dividendo02 giu 2022
Stima target 1A259,76
  • GlobeNewswire

    BioNTech Announces First Quarter Financial Results and Corporate Update

    First quarter revenues of €6.4 billion1, net income of €3.7 billion and fully diluted earnings per share of €14.24 ($15.972)Reiterates BioNTech COVID-19 2022 vaccine revenue guidance of €13 billion to €17 billionFirst-in-class CAR-T program targeting CLDN-6 (BNT211) in solid tumors showed manageable safety profile and signs of clinical activity; preliminary Phase 1/2 data presented at AACR Annual Meeting 2022Continued pipeline expansion to 16 clinical stage oncology programs in 20 ongoing clinic

  • GlobeNewswire

    BioNTech to Report First Quarter 2022 Financial Results and Operational Update on May 9, 2022

    Mainz, Germany, April 26, 2022 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2022 on Monday, May 9th, 2022. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. EDT (2.00 p.m. CEST) to report its financial results and provide a corporate update for the first quarter 2022. The slide presentation and audio of the webcast wil

  • GlobeNewswire

    Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age

    Data from a subanalysis of 30 sera from a Phase 2/3 clinical trial of children 5 through 11 years of age show a 36-fold increase in SARS-CoV-2 Omicron neutralizing titers following a booster (third) dose of the Pfizer-BioNTech COVID-19 Vaccine In the Phase 2/3 clincal trial with 140 children a booster (third) dose of the Pfizer-BioNTech COVID-19 Vaccine increased neutralizing antibodies by 6-fold against the SARS-CoV-2 wild-type strain in this age groupCompanies plan to submit these data to U.S.